ArticleJournal of clinical microbiology2002
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Nogo-A and NfL Levels in CSF from Newly Diagnosed Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder Patients Positive for Anti-HHV6-A IgG Autoantibody.Journal of clinical medicine · 2025Article
- Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity.Microorganisms · 2022Article
- Human Herpesviruses 6A and 6B in Brain Diseases: Association versus Causation.Clinical microbiology reviews · 2020Review
- The U94 Gene of Human Herpesvirus 6: A Narrative Review of Its Role and Potential Functions.Cells · 2020Review
- HHV-6A Infection and Systemic Sclerosis: Clues of a Possible Association.Microorganisms · 2019Article
- Detection and Differentiation of Two Koala Gammaherpesviruses by Use of High-Resolution Melt (HRM) Analysis Reveals Differences in Viral Prevalence and Clinical Associations in a Large Study of Free-Ranging Koalas.Journal of clinical microbiology · 2019Article
- Laboratory and clinical aspects of human herpesvirus 6 infections.Clinical microbiology reviews · 2015Review
- Immune response to HHV-6 and implications for immunotherapy.Current opinion in virology · 2014Review
- Evidence linking HHV-6 with multiple sclerosis: an update.Current opinion in virology · 2014Review
- Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.Future virology · 2013Article
- Prevalence of human herpesvirus U94/REP antibodies and DNA in Tunisian multiple sclerosis patients.Journal of neurovirology · 2013Article
- Article
- Monitoring of active human herpes virus 6 infection in Iranian patients with different subtypes of multiple sclerosis.Journal of pathogens · 2013Article
- Imbalanced oxidative stress causes chlamydial persistence during non-productive human herpes virus co-infection.PloS one · 2012Article
- Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto's thyroiditis.PLoS pathogens · 2012Article
- The molecular biology of human herpesvirus-6 latency and telomere integration.Microbes and infection · 2011Review
- Early and late HHV-6 gene transcripts in multiple sclerosis lesions and normal appearing white matter.Brain : a journal of neurology · 2005Article
- Update on human herpesvirus 6 biology, clinical features, and therapy.Clinical microbiology reviews · 2005Review
- Human Herpesvirus 6 Infection of the Central Nervous System.Current infectious disease reports · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association between human herpesvirus 6 (HHV-6) and multiple sclerosis (MS) is controversial. In fact, it is difficult to establish a causative role of HHV-6, due to the high prevalence of latently infected individuals in the healthy population. Therefore, the presence of virus sequences in tissue biopsy does not support a viral role, and serological assays do not show significant differences between MS patients and control populations. The only viral gene expressed during latency is U94/rep. Therefore, we have developed a serological assay for the detection of antibodies specifically directed against U94/REP protein. Different populations were analyzed by enzyme-linked immunosorbent assay, including healthy controls, MS patients, and subjects with diseases unrelated to HHV-6 infection, including other neurological diseases. The results show statistically significant differences (P > 0.01) between MS patients and control groups, both in antibody prevalence (87 and 43.9%, respectively) and in geometric mean titer (1:515 and 1:190, respectively). The detection of antibodies specific for HHV-6 U94/REP shows that the immune system is exposed to this antigen during natural infection. The higher prevalence and higher titers of antibodies to U94/REP suggest that MS patients and control groups might experience different exposures to HHV-6.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.